CymaBay Therapeutics (CBAY) Stock Forecast & Price Target

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)

$32.48

0.00 (0.00%)

(As of 04/1/2024)

CymaBay Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 12 Analyst Ratings

Analysts' Consensus Price Target

$28.65
-11.79% Downside

High Forecast	$32.50
Average Forecast	$28.65
Low Forecast	$15.00

Type	Current Forecast 4/20/23 to 4/19/24	1 Month Ago 3/21/23 to 3/20/24	3 Months Ago 1/20/23 to 1/20/24	1 Year Ago 4/20/22 to 4/20/23
Consensus Rating	Hold	Hold	Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	12 Buy rating(s)	7 Buy rating(s)
Hold	11 Hold rating(s)	11 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$28.65	$28.65	$22.64	$13.50
Predicted Upside	-11.79% Downside	2.39% Upside	58.79% Upside	80.56% Upside

Get CymaBay Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter.

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

CBAY Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CBAY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CymaBay Therapeutics Stock vs. The Competition

Type	CymaBay Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.08	2.68	2.49
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	-11.79% Downside	928.01% Upside	12.31% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/29/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Arce Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$32.50	+0.71%
2/20/2024	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Market Perform	$32.50	+0.99%
2/14/2024	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Jubinville Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
2/14/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Neutral	$33.00 ➝ $32.50	+1.18%
2/14/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Neutral	$25.00 ➝ $32.50	+1.18%
2/13/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Neutral
Get the Latest News and Ratings for CBAY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
2/13/2024	Jonestrading Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
2/13/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Kluska Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$32.50	+0.90%
2/13/2024	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Neutral	$29.00 ➝ $32.50	+0.90%
2/13/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$32.50	+0.90%
2/12/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hsieh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/11/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$20.00	+54.32%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 02:56 AM ET.

CBAY Price Target - Frequently Asked Questions

What is CymaBay Therapeutics's consensus rating and price target?: According to the issued ratings of 12 analysts in the last year, the consensus rating for CymaBay Therapeutics stock is Hold based on the current 11 hold ratings and 1 buy rating for CBAY. The average twelve-month price prediction for CymaBay Therapeutics is $28.65 with a high price target of $32.50 and a low price target of $15.00. Learn more on CBAY's analyst rating history.
Do Wall Street analysts like CymaBay Therapeutics more than its competitors?: Analysts like CymaBay Therapeutics less than other Medical companies. The consensus rating for CymaBay Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how CBAY compares to other companies.
Is CymaBay Therapeutics being downgraded by Wall Street analysts?: Over the previous 90 days, CymaBay Therapeutics's stock had 5 downgrades by analysts.

Does CymaBay Therapeutics's stock price have much upside?: According to analysts, CymaBay Therapeutics's stock has a predicted upside of 2.39% based on their 12-month stock forecasts.
What analysts cover CymaBay Therapeutics?: CymaBay Therapeutics has been rated by B. Riley, BTIG Research, Cantor Fitzgerald, HC Wainwright, Jonestrading, Lifesci Capital, Piper Sandler, Raymond James, SVB Leerink, UBS Group, and William Blair in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:CBAY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

CymaBay Therapeutics (CBAY) Stock Forecast & Price Target

CymaBay Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

Analysts' Consensus Rating

Analysts' Consensus Price Target

CBAY Analyst Ratings By Month

CBAY Price Targets by Month

CymaBay Therapeutics Stock vs. The Competition

Recent Analyst Ratings and Stock Forecasts

CBAY Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info